TVGN Stock Price | Tevogen Bio Holdings Inc P/E, Revenue, EPS, & Forecasts

Tevogen Bio Holdings Inc • TVGN

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Tevogen Bio Holdings Inc

Ticker

TVGN

Trading on

NASDAQ

ISIN

US88165K1016

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.

Headquarters

15 Independence Boulevard, Warren, NJ, United States, 07059

Employees

Website

https://tevogen.com

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Metrics

BasicAdvanced

Market cap

$85M

P/E ratio

EPS

-$0.18

Dividend Yield

0.00%

Beta

-0.85

Forward P/E ratio

EBIDTA

$-30.7M

Ex dividend date

Price & volume

Market cap

$85M

Average daily volume

0.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

Earnings

EPS

-$0.18

EPS estimate (current quarter)

-$0.06

EPS estimate (next quarter)

-$0.06

EBITDA

$-30.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-0.85

52-week High

$1.92

52-week Low

$0.38

50-day moving average

$0.60

200-day moving average

$0.98

Short ratio

4.39

Short %

3.73%

Management effectiveness

ROE (TTM)

0.00%

ROA (TTM)

-439.67%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

199M

Float

24.6M

Insiders %

78.57%

Institutions %

2.55%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$5.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.05

Q4 • 24Beat

-$0.07

-$0.05

-40.00%

Q1 • 25Missed

-$0.03

-$0.05

40.00%

Q2 • 25Beat

-$0.03

-$0.06

50.00%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-5.5M

-∞%

Q2 • 25

$0M

$-5.7M

-∞%

Q3 • 25

NaN%

4.05%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$4.3M

$13.8M

322.17%

Q2 • 25

$4.5M

$12.3M

274.11%

Q3 • 25

5.26%

-10.44%

-14.92%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-3.2M

$0M

$1.9M

$-3.2M

Q2 • 25

$-3.6M

$0M

$4M

$-3.6M

Q3 • 25

14.42%

110.60%

14.42%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Tevogen Bio Holdings Inc share?

Tevogen Bio Holdings Inc shares are currently traded for undefined per share.

How many shares does Tevogen Bio Holdings Inc have?

Tevogen Bio Holdings Inc currently has 199M shares.

Does Tevogen Bio Holdings Inc pay dividends?

No, Tevogen Bio Holdings Inc doesn't pay dividends.

What is Tevogen Bio Holdings Inc 52 week high?

Tevogen Bio Holdings Inc 52 week high is $1.92.

What is Tevogen Bio Holdings Inc 52 week low?

Tevogen Bio Holdings Inc 52 week low is $0.38.

What is the 200-day moving average of Tevogen Bio Holdings Inc?

Tevogen Bio Holdings Inc 200-day moving average is $0.98.

Who is Tevogen Bio Holdings Inc CEO?

The CEO of Tevogen Bio Holdings Inc is Dr. Ryan H. Saadi M.D., M.P.H, M.P.H..

How many employees Tevogen Bio Holdings Inc has?

Tevogen Bio Holdings Inc has 18 employees.

What is the market cap of Tevogen Bio Holdings Inc?

The market cap of Tevogen Bio Holdings Inc is $85M.

What is the P/E of Tevogen Bio Holdings Inc?

The current P/E of Tevogen Bio Holdings Inc is null.

What is the EPS of Tevogen Bio Holdings Inc?

The EPS of Tevogen Bio Holdings Inc is -$0.18.

What is the PEG Ratio of Tevogen Bio Holdings Inc?

The PEG Ratio of Tevogen Bio Holdings Inc is null.

What do analysts say about Tevogen Bio Holdings Inc?

According to the analysts Tevogen Bio Holdings Inc is considered a buy.